Literature DB >> 11279945

Attenuation by butalbital of capsaicin-induced c-fos-like immunoreactivity in trigeminal nucleus caudalis.

F M Cutrer1, D D Mitsikostas, G Ayata, M Sanchez del Rio.   

Abstract

We examined the effects of butalbital (30, 100, and 1000 micrograms/kg) on the number of cells expressing c-fos-like immunoreactivity (c-fos-LI), a marker of neuronal activation, within lamina I, IIo of the trigeminal nucleus caudalis and the nucleus of the solitary tract 2 hours after the intracisternal injection of capsaicin (0.1 mL; 15.25 mg/mL) or vehicle in urethane-anesthetized guinea pigs (N = 45). Robust c-fos-LI was observed within nuclei of cells in the trigeminal nucleus caudalis after capsaicin (329 +/- 35). Butalbital dose-dependently reduced the number of labeled cells to a maximum of 66% (1000 micrograms/kg intraperitoneally [i.p.], P < .01) in lamina I, IIo but not within area postrema, medial reticular nucleus, or the nucleus of the solitary tract. Pretreatment with bicuculline (30 micrograms/kg i.p.) blocked the effect of butalbital, thereby suggesting the importance of the GABAA receptor to activation involved in the transmission of nociceptive information. Our studies suggest the possibility that GABAA receptors might provide an important therapeutic target in migraine and related headache disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11279945     DOI: 10.1046/j.1526-4610.1999.3910697.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  2 in total

1.  The α6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation.

Authors:  Pi-Chuan Fan; Tzu-Hsuan Lai; Chia Chun Hor; Ming Tatt Lee; Pokai Huang; Werner Sieghart; Margot Ernst; Daniel E Knutson; James Cook; Lih-Chu Chiou
Journal:  Neuropharmacology       Date:  2018-07-21       Impact factor: 5.250

2.  Age-Dependent Anti-migraine Effects of Valproic Acid and Topiramate in Rats.

Authors:  Pokai Huang; Ping-Hung Kuo; Ming Tatt Lee; Lih-Chu Chiou; Pi-Chuan Fan
Journal:  Front Pharmacol       Date:  2018-09-25       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.